A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf.
Metastatic soft tissue sarcomas: update on new agents and clinical studies
2017
Cancer Breaking News
Preserved Fulltext
Soft tissue sarcomas are rare tumors of mesenchymal origin comprising about 1% of all adult malignant diseases. Systemic therapy for locally advanced and metastatic disease was restricted for decades to a few effective and approved agents, such as doxorubicin or ifosfamide. However, numerous clinical trials and new drug developments such as trabectedin, pazopanib, olaratumab or eribulin have recently enriched the therapeutic armamentarium in the treatment of patients with advanced soft tissue
doi:10.19156/cbn.2017.0042
fatcat:kipkitrzsbeildmybpwyctten4